Spectral CT System Gets FDA Clearance for Radiation Oncology Use
The Spectral CT 7500 RT system reportedly combines 4D conventional computed tomography (CT) with the enhanced quantification and visualization of spectral CT to facilitate improved precision with radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Spectral CT 7500 RT system, which enables clinicians to access the capabilities of 4D conventional computed tomography (CT) and spectral CT in one scan.
Geared to radiation oncology, the Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, facilitating targeted radiotherapy, according to Philips, the manufacturer of the Spectral CT 7500 RT system.
The newly FDA-cleared Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, and offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing. (Image courtesy of Philips.)
Emphasizing that the Spectral CT 7500 RT system is the first radiation therapy CT platform to provide respiratory-gated spectral imaging, Philips said the system offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing.
"The Spectral CT system provides us with several capabilities that conventional CT does not have. It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio. And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning," noted Zhong Su, Ph.D., the physics director in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas.
Philips noted the Spectral CT 7500 RT system will be showcased at the upcoming Radiological Society of North America (RSNA) Annual Meeting in Chicago December 1-5, 2024.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
